An interventional study of Multi-Theory Model (MTM)-Based Smoking Cessation Program in Tobacco Use Disorder/Cigarette Smoking, sponsored by University of Nevada, Las Vegas. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 29 Years. Per ClinicalTrials.gov, last updated 2025-08-11.
Sponsored by University of Nevada, Las Vegas · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 799 studies in Tobacco Use Disorder with a site in United States — 75 open to participants now, 91 under way, 5 of them phase 3. Tobacco Use Disorder · United States.
Among the 799 studies in Tobacco Use Disorder with a site in United States, this one is the 259th largest by planned enrollment of the 736 interventional ones that give a count, is one of 23 that started in 2025, is one of 364 with no phase, reaches primary completion later than 3 of the 90 other live ones, and was the 774th registered.
1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.
Browse Tobacco Use Disorder studies →75 of the 799 studies in Tobacco Use Disorder with a site in United States are open now. Recruiting first, the newest first:
Florida International University · Sites in United States
Ages 14–18
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 21+ · Healthy volunteers
VA Office of Research and Development · Sites in United States
Ages 21+
VA Office of Research and Development · Sites in United States
Yale University · Sites in United States
Ages 21–44 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.
This study: 18 Years to 29 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
799 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 110 · Phase 2 176 · Phase 3 66 · Phase 4 71
First in 1990; this study’s year is marked. 23 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 144 is above the median of 90 across 893 interventional studies indexed under Tobacco Use Disorder.
Median enrollment 84 across the 736 interventional studies, 112 across the 58 observational. Of the 656 that completed or were terminated, 344 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 799 have an industry lead sponsor. The 10 most frequent:
University of Nevada, Las Vegas is the lead sponsor of 75 studies on the registry; 22 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
University of Nevada, Las Vegas has 1 study filed under Tobacco Use Disorder — fewer than ten, so there is no comparison to draw.
41 of the studies in Tobacco Use Disorder with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04176172Phase 3Abramson Cancer Center at Penn MedicineOptimizing Tobacco Use Treatment for PLWHA | 2026-11-30 |
| NCT06837220University of ChicagoImplementation of Tobacco Cessation Programming at Community Behavioral Health Sites | 2026-12 |
| NCT05452772Johns Hopkins University5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder | 2026-12 |
| NCT07322432VapeAwayThe CONQUER Trial - Cessation Of Nicotine, QUitting With E-cigarette Reduction | 2026-12 |
| NCT06617312University of California, Los AngelesExamining the Effects of Cytisinicline on Neural Substrates of Cigarette Cue-reactivity | 2026-12 |
Add all 41 to your calendar (.ics) → With an account.
Among the 799 studies in Tobacco Use Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate whether a Multi-Theory Model (MTM)-based behavioral intervention can effectively promote smoking cessation and support behavior change in young adult cigarette smokers aged 18 to 29 in the United States. This trial focuses on whether applying theory-driven strategies such as emotional transformation, behavioral confidence, and participatory dialogue can lead to higher smoking abstinence rates and improved psychosocial outcomes compared to a standard knowledge-based smoking education control group.
The main questions it aims to answer are:
Participants will:
Be randomly assigned to one of two groups:
o MTM-Based Intervention Group: Attend four weekly 90-minute virtual group sessions covering: Week 1: Participatory dialogue, behavioral confidence, and process evaluation Week 2: Emotional transformation, environmental restructuring, and process evaluation Week 3: Practice for change, relapse prevention, and process evaluation Week 4: Social support, reward systems, and process evaluation
o Knowledge-Based Control Group: Attend four weekly 90-minute didactic virtual sessions focused on: Smoking-related health risks Overview of FDA-approved smoking cessation tools
This trial will be conducted entirely online and follows a randomized controlled trial (RCT) design with a 1:1 group allocation ratio. A total of 144 participants (approximately 72 per group) will be recruited, accounting for an expected attrition rate of up to 50%. This sample size was chosen to ensure sufficient power to detect statistically significant differences between the two groups (effect size f = 0.25, α = 0.05, power = 0.80).
Although the intervention will be delivered virtually, the study is affiliated with the University of Nevada, Las Vegas (UNLV), which provides IRB approval, secure data storage infrastructure, and institutional oversight (IRB Protocol #2024-453). Informed consent will be obtained electronically, and all participant data will be securely stored using encrypted Qualtrics surveys and password-protected UNLV or Google Drive servers with limited access, ensuring full confidentiality and ethical compliance.
This trial addresses a pressing public health challenge: the persistent difficulty young adults face in quitting smoking despite decades of tobacco control efforts. Young adults remain a high-risk population for relapse and are frequently underserved by conventional cessation programs. This MTM-based intervention seeks to fill this gap by targeting both behavioral and environmental barriers through structured, evidence-based strategies designed to build self-efficacy, emotional readiness, and environmental support.
The use of MTM constructs such as emotional transformation, behavioral confidence, and restructuring the physical/social environment is a key innovation that may enhance long-term cessation outcomes. Moreover, delivering the program virtually increases its potential for scalability and real-world application, making it a promising model for public health programs nationwide.
The findings of this clinical trial will be disseminated through peer-reviewed journal articles, national public health conferences (APHA, SOPHE etc.), and shared with stakeholders like the CDC's Office on Smoking and Health. The results may help shape future funding priorities, guide the development of policy, and inform the design of tailored interventions for smoking cessation among young adults.
Introduction Tobacco use continues to be a major contributor to preventable disease, disability, and death worldwide. In the United States, despite a general decline in smoking prevalence over the past decades, young adults aged 18-29 continue to demonstrate concerning rates of smoking initiation and persistent use. According to the CDC (2022), approximately 13.8% of individuals in this age group are current cigarette smokers. This prevalence underscores the urgent need for tailored, developmentally appropriate interventions.
Young adulthood is a transitional period marked by increased autonomy, identity exploration, and greater susceptibility to risk-taking behaviors. These developmental vulnerabilities are compounded by stress, peer influence, and underdeveloped coping mechanisms, making smoking both an appealing coping strategy and a challenging habit to break. Many young adults begin smoking due to social pressures or emotional distress and struggle to quit due to nicotine addiction, insufficient resources, or low behavioral confidence. Alarmingly, although 67.7% of young adult smokers express a desire to quit, only 8.8% successfully do so.
Smoking-related illnesses claim more than 480,000 lives annually in the U.S. and afflict over 16 million people. Globally, over 1.3 billion people use tobacco, with young adults comprising a substantial proportion. In the U.S., daily smoking among young adults rose from 38.7% to 55.9%, and initiation rates climbed from 20.6% in 2002 to 42.6% in 2018. Disparities are even more severe among marginalized groups including low-income populations, racial/ethnic minorities, and LGBTQ+ individuals due to factors like targeted tobacco marketing, limited access to culturally sensitive care, and socioeconomic barriers.
Multiple factors contribute to sustained tobacco use among young adults. Biologically, neurodevelopmental immaturity and genetic predisposition increase susceptibility to nicotine addiction. Psychologically, factors such as anxiety, depression, impulsivity, and stress drive smoking behavior. Social influences including peer norms and social modeling strongly affect initiation and continuation. Environmental exposures to tobacco advertising and inadequate policy enforcement further exacerbate these risks.
The short- and long-term health consequences of smoking are well-documented. Acute effects include impaired lung function, increased heart rate, and elevated blood pressure. Chronic exposure leads to diseases such as COPD, cardiovascular disease, and various cancers. Reproductive health is also compromised, with links to infertility and pregnancy complications.
Moreover, smoking exacerbates mental health conditions and impairs stress coping. Despite the known risks, many young adults lack access to evidence-based, culturally relevant, and behaviorally grounded cessation interventions. Existing programs often rely on outdated models developed for adolescents or older adults, failing to meet the psychological and contextual needs of younger populations. Although digital platforms offer new opportunities, high attrition rates and lack of theoretical grounding limit their effectiveness.
Background and Rationale
2.1 Public Health Significance Tobacco-related illness remains a leading cause of preventable death in the U.S., with substantial social and economic burdens. Intervening in young adulthood, before lifelong patterns are firmly established, presents a crucial opportunity to reduce future morbidity and mortality.
2.2 Theoretical Framework While traditional behavioral models like the Transtheoretical Model (TTM), Social Cognitive Theory (SCT), and Health Belief Model (HBM) have been widely used in cessation programs, they often treat behavior change as linear or static. These limitations reduce their effectiveness in addressing the fluctuating motivations and emotional stressors common among young adults.
This study utilizes the Multi-Theory Model (MTM) of Health Behavior Change, a dynamic and integrative framework that distinguishes between initiation and sustenance phases. MTM constructs include participatory dialogue (weighing pros and cons), behavioral confidence (akin to self-efficacy), changes in the physical environment, emotional transformation, practice for change, and restructuring the social environment. MTM has demonstrated effectiveness in various public health contexts and is particularly well-suited to the diverse and evolving behavioral patterns of young adults.
2.3 Evidence Gap Despite MTM's theoretical promise, its application to smoking cessation in young adults is limited. Most available programs fail to incorporate emotional regulation, peer support, or environmental restructuring components that are central to sustained behavior change in this age group. Furthermore, culturally and developmentally tailored interventions remain scarce, leaving many at-risk young adults underserved. This study represents one of the first attempts to systematically apply and evaluate MTM constructs in a targeted smoking cessation intervention for this population.
By designing an MTM-based intervention specifically for young adults, this research aims to fill a critical gap in the public health literature and contribute a replicable, theory-driven model for future cessation programs.
Study Objectives
3.1 Primary Objectives
3.2 Secondary Objectives
Study Design This study utilizes a two-arm, parallel-group randomized controlled trial (RCT) design to rigorously assess the effectiveness of a Multi-Theory Model (MTM)-based behavioral intervention compared to a knowledge-based smoking cessation intervention. The trial will be entirely conducted online through secure digital platforms (Qualtrics). This fully virtual format was chosen to enhance participant accessibility, especially for geographically diverse populations, and to optimize participant retention over the study duration. The RCT design adheres to CONSORT guidelines for non-pharmacological trials, providing a robust methodological framework for evaluating behavioral interventions.
Eligible participants will be randomized at the individual level in a 1:1 ratio to one of two intervention arms: (1) an MTM-based behavioral intervention (experimental group) or (2) a knowledge-based control intervention. Randomization will be implemented using a computer-generated allocation sequence with block sizes of four, ensuring balanced group assignment. Stratification by gender and baseline nicotine dependence will be considered to control for potential confounding.
The intervention period spans four consecutive weeks, during which participants will attend one 90-minute session per week. All sessions will be delivered via encrypted Google Meet to ensure confidentiality and standardization across groups.
Intervention Arms
5.1 MTM-Based Intervention (Experimental Group) The experimental condition is informed by the Multi-Theory Model of Health Behavior Change (MTM), which includes both initiation and sustenance constructs. The intervention content was developed in alignment with validated MTM constructs, incorporating participatory pedagogy and cognitive-behavioral strategies. Each weekly session will be co-facilitated by a trained public health graduate student under supervision of academic advisor. A process evaluation will be conducted at the end of each session using the Reach, Quality control, Fidelity, Satisfaction and Management (RQFSM).
Session Overview:
5.2 Knowledge-Based Intervention (Control Group) Participants in the control group will receive didactic information on smoking cessation strategies, mimicking standard public health education. Content is aligned with U.S. Public Health Service guidelines on tobacco treatment but excludes MTM-based constructs.
Session Overview:
Compensation: Each participant will receive a $10 Amazon e-gift card after completing each of the four intervention sessions, with an additional $10 awarded upon completing the 12-week follow-up assessment, for a total of up to $50. Participants who do not complete all sessions will receive partial incentives based on their level of participation. These incentives are not funded by any external organization or grant but are personally covered by the co-investigator as part of fulfilling the requirements for his doctoral degree.
Amazon e-gift cards were selected as incentives because they offer a convenient, digital delivery method that aligns with our online intervention. Importantly, Amazon does not sell tobacco products, which helps promote a smoke-free lifestyle and reinforces participants' commitment to quitting. This choice also minimizes logistical barriers while supporting the study's health objectives.
Data Collection and Management
9.1 Timepoints:
9.2 Data Collection Tools: All instruments will be administered through Qualtrics, a Health Insurance Portability and Accountability Act (HIPAA)-compliant survey platform. Instruments include (49 items in total):
9.3 Data Management: Data will be stored on UNLV's secure, encrypted servers and accessed only by authorized research personnel. Each participant will be assigned a unique identifier to ensure anonymity. Weekly data integrity checks and compliance with General Data Protection Regulation (GDPR) and HIPAA standards will be ensured.
9.4 Missing Data: Missing data will be handled using Multiple Imputation (MI) under the assumption of Missing at Random (MAR).
Dissemination Plan
Research findings will be shared with both academic and public health audiences. Planned dissemination channels include:
Moreover, the integration of behavior change theory with digital health interventions aligns with national strategic priorities in tobacco control, such as those outlined in the FDA's Comprehensive Plan for Tobacco and Nicotine Regulation and the Healthy People 2030 objectives.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants are individually randomized to the control arm receive a four-week educational program focusing on basic information about the health risks of smoking and effective quitting techniques. The program consists of weekly 90-minute sessions delivered in an online format to maximize participant reach and accessibility. Sessions cover topics such as smoking-related health consequences, benefits of quitting, common barriers to cessation, and practical strategies for quitting smoking. Unlike the experimental arm, this program does not include behavior change techniques grounded in the Multi-Theory Model but instead emphasizes increasing awareness and knowledge to motivate cessation. This active comparator arm serves to control for time and attention while providing participants with standard smoking cessation information.
Behavioral: Multi-Theory Model (MTM)-Based Smoking Cessation Program
This arm delivers a four-week smoking cessation intervention grounded in the Multi-Theory Model (MTM) of health behavior change. Participants are individually randomized into two arms of the study to ensure comparability between groups and reduce selection bias. The intervention comprises weekly 90-minute sessions delivered entirely online, with a focus on core MTM constructs: participatory dialogue, behavioral confidence, emotional transformation, practice for change, and changes in physical and social environment. Session activities include storytelling, interactive discussions weighing quitting pros and cons, confidence-building exercises, role-playing high-risk situations, emotional expression and transformation techniques, development of supportive social networks, stress management tools, reflection and reward practices, and commitment reinforcement through letters and group sharing.
Behavioral: Multi-Theory Model (MTM)-Based Smoking Cessation Program
Multi-Theory Model (MTM)-Based Smoking Cessation Program: A four-week online smoking cessation program based on the Multi-Theory Model (MTM). It uses behavior change strategies including participatory dialogue, building confidence, emotional transformation, practice for change, and changes in physical and social environment. Activities include storytelling, role-playing high-risk situations, emotional regulation, social support, stress management, reflection, and commitment exercises. The goal is to help young adults initiate and maintain quitting smoking. Knowledge-Based Smoking Risk Education and Quit Strategies Program: A four-week, online educational program providing information on smoking risks, benefits of quitting, barriers, and practical quit strategies. This control arm focuses on increasing knowledge and awareness but does not include MTM-based behavior change techniques.
Fagerström Test for Nicotine Dependence (FTND) measure
This outcome measures changes in nicotine dependence using the Fagerström Test for Nicotine Dependence (FTND), a validated 6-item questionnaire assessing the intensity of physical addiction to nicotine. Scores range from 0 to 10, with higher scores indicating greater dependence. Participants complete the FTND at baseline (pre-intervention) and again at the 12-week follow-up. The difference in scores over time is used to evaluate whether the intervention reduces nicotine dependence among young adult smokers. This helps assess the impact of the intervention beyond smoking cessation, providing insight into reductions in the psychological and physiological aspects of tobacco addiction. Repeated Measures Analysis of Covariance (ANCOVA) will be used to examine changes in continuous outcomes (e.g., MTM construct scores, FTND scores) across the three time points. Baseline values and individual-level covariates (e.g., age, gender, baseline dependence) will be included as covariates.
Time frame: Baseline to 12 week followup
7-day point prevalence abstinence (PPA)
The 7-day point prevalence abstinence (PPA) measures whether participants have refrained from smoking defined as no tobacco use, not even a single puff during the 7 days prior to the 12-week follow-up. This outcome is assessed through participant self-report using a standardized questionnaire. To enhance accuracy, abstinence may be optionally validated using a carbon monoxide (CO) breath analyzer, with CO levels ≤6 parts per million (ppm) indicating non-smoking status. This measure helps determine the short-term effectiveness of the intervention in promoting smoking cessation among young adults.
Time frame: 12-week follow-up after baseline assessment
Changes in mean scores of MTM constructs using a validated 28-item MTM instrument
This outcome measures changes in participants' behavioral and psychological readiness to quit smoking using a validated 28-item questionnaire based on the Multi-Theory Model (MTM) of health behavior change. The instrument assesses six key MTM constructs: participatory dialogue, behavioral confidence, changes in the physical environment, emotional transformation, practice for change, and changes in the social environment. Each construct is measured using a set of Likert-scale items (e.g., 1 = Not at all sure to 5 = Completely sure). Participants complete the survey at baseline, immediately after the 4-week intervention, and at a 12-week follow-up. Mean scores are calculated for each construct at each time point to assess changes in smoking-related beliefs and behaviors over time. Generalized Linear Mixed Models (GLMM) with a logit link will assess differences in binary outcomes (PPA and quit rates) over time, incorporating fixed effects for group, time, and group × time interaction.
Time frame: Time of enrollment to 12 week followup
Quit rate
This outcome measures the self-reported quit rate, defined as the proportion of participants who successfully refrained from smoking for at least 24 consecutive hours with the intention of permanent cessation. Participants are asked whether they made any such quit attempts during the entire study period, particularly between baseline and the 12-week follow-up. A quit attempt is considered valid only if it reflects a deliberate and conscious effort to quit smoking entirely. This measure provides meaningful insight into participants' motivation and readiness to quit, even if sustained abstinence was not achieved. Tracking 24-hour quit rates at follow-up enables evaluation of the behavioral impact of the intervention on smoking cessation efforts among young adults.
Time frame: Baseline to 12-week follow-up
Plan to share: Yes — De-identified and aggregate-level data will be shared, including summary statistics such as group mean changes, average age, and proportions by gender and other relevant characteristics. This may include aggregated MTM construct scores, smoking status, quit attempts, and 7-day point prevalence abstinence outcomes. Data will be shared for academic research and secondary analysis to promote transparency and advance understanding of smoking cessation interventions. All personal identifiers will be removed to protect confidentiality. IPD will be made available upon reasonable request following publication of the primary results and with approval from the principal investigator and institutional review board (IRB).
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: June 2026, for 3 years
Access criteria: Qualified researchers affiliated with academic institutions or public health organizations may request access to these de-identified, aggregate-level data and supporting materials such as study protocols, data dictionaries, and analysis plans. Access will be granted for non-commercial, scholarly research following submission of a formal proposal outlining study aims and analysis plans. Approval from the principal investigator and the institutional review board (IRB) may be required. Upon approval, data will be shared via a secure platform or encrypted file transfer to maintain confidentiality and data integrity. All recipients must sign a data use agreement prohibiting any attempt to re-identify participants or redistribute the data.
Start is estimated for Nov 2025; primary completion for Dec 2025, 1 month later.
Of 257 non-industry interventional studies with no phase under Tobacco Use Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 1 month is below that.
Counting every sponsor, half of 267 studies reached it within 32 months; a quarter within 16 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Nevada, Las Vegas